Revenue more than doubled in 2025 following the successful launch of three cornerstone products: Incrolix, Galzyn, and Kinduvi.
Management attributes the 83% year-over-year Q4 revenue growth to increased sales of Alkindi Sprinkle and the addition of revenue from Incralex, Galzan, and Candivy.
The adjusted EBITDA margin expanded to 29% from 18%, driven by disciplined cost management and a shift toward higher-margin rare disease assets.
The Hemangiol acquisition follows a value-creation strategy of acquiring under-optimized assets to apply Eton’s specialized rare disease commercial infrastructure.
Galzin performance exceeded internal expectations, reaching 300 active patients within one year by converting users from non-FDA-approved over-the-counter zinc supplements.
Strategic positioning focuses on ‘Eton Cares,’ a patient support program designed to eliminate financial barriers and improve physician prescribing confidence.
2026 guidance projects revenue exceeding $110 million with adjusted EBITDA margins of at least 30% as the portfolio scales.
Management set a new ‘200 by 27’ goal, aiming for a $200 million revenue run rate by the end of 2027 through organic growth and at least one additional acquisition.
The Desmota launch strategy includes a 90-day pilot targeting adult endocrinologists to capture an addressable market three times larger than the pediatric population.
Long-term financial targets include reaching a 50% adjusted EBITDA margin by 2028 and $500 million in annual revenue by 2030.
The R&D pipeline is expected to be at its busiest in 2026, with five clinical studies planned to support label expansions and new NDAs.
The loss of the FDA small business exemption will result in $3.5 million in annual program fees, adding $2.8 million in incremental SG&A for 2026.
The Hemangiol integration includes hiring seven dedicated commercial employees from the seller to maintain momentum during the May 1 relaunch.
Gross margins may face temporary dilution in early 2026 due to lower-margin Incralex orders from international licensing partners.
The $14 million Hemangiol acquisition was funded entirely with cash on hand, avoiding shareholder dilution or new debt.
Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we’ll show you why it’s our #1 pick. Tap here.
Story Continues
